粪便微生物群移植治疗复发性或难治性艰难梭菌感染及其他潜在适应症:英国胃肠病学会(BSG)与医疗感染学会(HIS)联合指南第二版
该指南为英国胃肠病学会(BSG)与医疗感染学会(HIS)联合发布的第二版粪便微生物群移植(FMT)指南,采用英国国家卫生与临床优化研究所(NICE)认可的方法学制定。指南分为推荐意见、良好实践要点及反对某些实践的推荐,重点涵盖艰难梭菌感染(CDI)的FMT给药时机、胶囊制剂经验及供体筛查优化,并涉及非CDI适应症、特殊情况和FMT与微生物组治疗的发展。
要点
- FMT用于CDI时,重点聚焦给药时机、胶囊制剂的临床经验积累及供体筛查的优化。
- 供体筛查因COVID-19大流行及FMT相关病原体传播导致患者发病和死亡病例而尤为重要。
- 指南还评估了FMT在非CDI适应症(包括胃肠道和非胃肠道)中的新兴文献,并审查了相关随机对照试验。
核心结论
- 第二版BSG/HIS FMT指南基于过去5年显著增长的证据基础(包括大型国家FMT登记处的结局发表)更新,对英国临床医生尤其相关,但旨在具有国际适用性。
- 指南就FMT治疗CDI的给药时机、胶囊制剂经验及供体筛查优化提出推荐,并涉及非CDI适应症、特殊情况和FMT与微生物组治疗的发展。
研究设计与样本
- 由英国胃肠病学会(BSG)与医疗感染学会(HIS)联合制定,采用英国国家卫生与临床优化研究所(NICE)认可的方法学。
- 指南分为推荐意见、良好实践要点和反对某些实践的推荐。
主要发现
- 过去5年证据基础显著增长,包括大型国家FMT登记处的结局发表。
- COVID-19大流行及FMT相关病原体传播导致患者发病和死亡病例,使供体筛查主题尤为相关。
- 指南考虑了FMT在非CDI适应症(包括胃肠道和非胃肠道)中的新兴文献,并审查了相关随机对照试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The first British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS)-endorsed faecal microbiota transplant (FMT) guidelines were published in 2018. Over the past 5 years, there has been considerable growth in the evidence base (including publication of outcomes from large national FMT registries), necessitating an updated critical review of the literature and a second edition of the BSG/HIS FMT guidelines. These have been produced in accordance with National Institute for Health and Care Excellence-accredited methodology, thus have particular relevance for UK-based clinicians, but are intended to be of pertinence internationally. This second edition of the guidelines have been divided into recommendations, good practice points and recommendations against certain practices. With respect to FMT for Clostridioides difficile infection (CDI), key focus areas centred around timing of administration, increasing clinical experience of encapsulated FMT preparations and optimising donor screening. The latter topic is of particular relevance given the COVID-19 pandemic, and cases of patient morbidity and mortality resulting from FMT-related pathogen transmission. The guidelines also considered emergent literature on the use of FMT in non-CDI settings (including both gastrointestinal and non-gastrointestinal indications), reviewing relevant randomised controlled trials. Recommendations are provided regarding special areas (including compassionate FMT use), and considerations regarding the evolving landscape of FMT and microbiome therapeutics.
引用
- Mullish BH, Merrick B, Quraishi MN, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2024. PMID: 38609165. doi:10.1136/gutjnl-2023-331550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。